Background {#S0001}
==========

*Helicobacter pylori* is a spiral-shaped gram-negative bacteria which colonize the gastric or intestinal mucosa of humans and induce histologic inflammation.[@CIT0001],[@CIT0002] It is associated with peptic ulcer, gastritis and cancer.[@CIT0002],[@CIT0003] The infection of *H. pylori* remains a prevalent and worldwide chronic disease. It causes more than 90% and 80% of duodenal and gastric ulcers, respectively.[@CIT0001],[@CIT0004] This shows the world population is highly infected with *H. pylori*. About one-third of the adult population residing in Northern Europe and Northern America were found infected with *H. pylori*. Moreover, above 50% of population living in Southern and Eastern Europe, South America and Asia were infected with *H*.pylori. This was over pronounced in immigrants coming from countries with higher prevalence of *H. pylori*.[@CIT0005]

Worldwide, various eradication strategies are proposed for the treatment of *H. pylori* infection including triple therapy, sequential therapy, concomitant therapy, quadruple therapy and hybrid therapy.[@CIT0006],[@CIT0007] The Maastricht IV Florence Consensus report overemphasized, eradication of *H. pylori* infection produces a long-term relief of dyspepsia. However, a long-term treatment with proton pump inhibitors is associated with the development of a corpus-predominant gastritis which accelerates to the development of atrophic gastritis.[@CIT0008]

Antibiotic resistance is nowadays the challenging issue in the treatment of bacterial infections. It is still continuing as global public health threat specifically in most of the major microbial pathogens.[@CIT0009],[@CIT0010] Similar to other bacterial resistances, *H. pylori* drug resistance is also the main factor affecting the efficacy of current treatment regimens.[@CIT0011] Various resistance mechanisms are described earlier however, point mutation on the surface of bacterial chromosome is described as the main causes of treatment failure due to drug resistance.[@CIT0012]

*H. pylori* resistance to antibiotics is the major cause of treatment failure.[@CIT0013] Patients with sensitive isolates of clarithromycin (CLR) isolates have shown 100% eradication compared to none of patients with CLR resistant isolates.[@CIT0014] This indicates CLR resistance was responsible for the treatment failure. In addition to this, there are different mechanisms of resistance the bacteria can remain unharmed. These includes redox intracellular potential, pump efflux systems and membrane permeability for medications including to CLR, metronidazole (MTR), Quinolones, amoxicillin (AMX) and tetracycline.[@CIT0015] Prolonged hospitalization and use of antibiotics without prescription were also indicated as major reasons for the increased incidence of bacterial resistance.[@CIT0016]

In vitro antibiotic susceptibility tests of *H. pylori* need standard culture because it is a relatively fastidious and slow-growing microaerophilic microorganism.[@CIT0017] Antibiotic susceptibility test helps in the proper prescribing and use of medications, and increase patient treatment outcome. Despite this, the trend of bacterial resistance is not yet recently studied which helps in the adoption of appropriate global and regional prevention strategies. Therefore, the purpose of this review was to systematically review and analyze existing published literature that presents estimates of primary antibiotic resistance of *H. pylori* in adult population.

Methods {#S0002}
=======

Search Strategy {#S0002-S2001}
---------------

Before beginning of the study, the recent publication of the research question was checked to prevent over duplication in PROSPERO International prospective register of systematic reviews and had registered with a registration number; CRD42017068710. A comprehensive systematic search was done using searching key terms; *H. pylori* antibiotic resistance, amoxicillin, clarithromycin, metronidazole, and levofloxacin adding Boolean terms OR, AND, and NOT to gather relevant articles of a consecutive three years (2015 to 2017). A search engines; PubMed/Medline and Google scholar were used to collect relevant literature ([[Supp 1 record identification](https://www.dovepress.com/get_supplementary_file.php?f=250200.docx)]{.ul}).

Eligibility Criteria {#S0002-S2002}
--------------------

Studies conducted in adult age group greater than eighteen, bacteria confirmed on endoscopic observation/diagnosis from gastric/duodenal biopsy, previously never taken *H. pylori* treatment, *H. pylori* infection without gastric/duodenal cancer, had no prior 2-weeks history of acid secretion inhibitors drug intake (proton pump inhibitors or H~2~-blockers), had not undergone gastric surgery and published in English language between 2015 and 2017 were the eligibility criteria for inclusion in the study.

Selection and Extraction of Data {#S0002-S2003}
--------------------------------

Data were extracted using a standardized pre-prepared table to collect similar evidence from each literature. The evidence extracted includes: author/s name and year of the study, study area or country, number of study participants, study period and prevalence estimate of antibiotic resistance. This was based on the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement for reporting systematic reviews and meta-analyses of studies flow chart ([Figure 1](#F0001){ref-type="fig"}).[@CIT0018]Figure 1PRISMA flow chart representation showing the overall searching and article selection process of a study *Helicobacter pylori* primary resistance pattern to antibiotics.**Note:** Adapted from Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. [<https://doi.org/10.1371/journal.pmed.1000097>]{.ul}.[@CIT0018]

Statistical Analysis {#S0002-S2004}
--------------------

An initial extraction and estimation of pooled prevalence using Wilson method of double arcsine transformations were done to estimate a confidence interval for a proportion of studies in Excel.[@CIT0019] A pooled overall prevalence rate was estimated with 95% confidence interval (CI). This was interpreted and compared among countries and continents.

Quality Assessment {#S0002-S2005}
------------------

Two reviewers (GGK and GTD) carried out the initial screening of the citations retrieved in the searches based on titles and abstracts followed by a full-text assessment of any article identified as being potentially eligible. Any discrepancies during the assessment had resolved by the team. Both reviewers have made a methodological quality assessment on the included eligible studies. The National Institute for Health research (NIH) based Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies was used to assess the methodological quality of studies included in the systematic review rating; good = 2, fair = 1 and poor (cannot be determined, not reported or not applicable) = 0.[@CIT0020]

Results {#S0003}
=======

Search results {#S0003-S2001}
--------------

Our searching process has retrieved a total of 288 publications which later resulted in 38 articles for full-text review. Among 38 articles reviewed in full text, 14 studies have been included for the study which fulfilled the inclusion criteria.[@CIT0021],[@CIT0024]--[@CIT0036] The selection and screening process is presented in detail (see [Figure 1](#F0001){ref-type="fig"}).

Characteristics of Studies {#S0003-S2002}
--------------------------

### Primary Resistance to Amoxicillin {#S0003-S2002-S3001}

Among patients (n=4218) previously never taken the treatment regimen, no resistance was reported in Europe and North America for AMX. In contrast to this, higher resistance rate was reported from Africa (17.7%). Asian and Latin American studies also reported comparable resistance pattern of 3.9% and 4.4%, respectively. A study conducted in Egypt, among 46 study participants almost half of them were non-susceptible to AMX. Similar to this, a study conducted in Nigeria and Peru reported one-third of *H. pylori* positive patients were non-susceptible. But, no resistances were seen in Morocco, Poland, Turkey, America, Canada and Nepal.

### Primary Resistance to Clarithromycin {#S0003-S2002-S3002}

Clarithromycin (CLR) is a Macrolide derivative used in the treatment of *H. pylori* eradication. CLR resistance has shown an association in predicting treatment failure of *H. pylori* eradication therapy.[@CIT0022] Comparable resistance rate was reported in Europe (31.3%) and Asia (30.9%) respectively. Within this the bacterial non-susceptibility rate was reported as 26.7% in Africa. Low rate of resistance was obtained in North America (18.5%) and South America (19.4) in comparison to other continents. Above half patients were non-susceptible in Poland, Egypt and China. *H. pylori* resistance of CLR has significantly increased in 2009--10 and 2013--14 as a study reported from china.[@CIT0021]

### Primary Resistance to Metronidazole {#S0003-S2002-S3003}

Metronidazole (MTR) is an alternative for penicillin-allergic candidates during *H. pylori* eradication therapy.[@CIT0008] Almost half of Asian patients were non-susceptible (48.9%) to MTR-based *H. pylori* treatment and higher rate of resistance was reported in Nigeria, Nepal, China, Peru and Poland with a prevalence rate of 99.1%, 88.1%, 66.8%, 61.8% and 56.7%, respectively.

### Primary Resistance to Levofloxacin {#S0003-S2002-S3004}

It is a promising Fluoroquinolones derivative used in the eradication of *H. pylori* infection.[@CIT0023] However, a substantial prevalence of resistance was observed especially in North America and Asia; 29.2% and 29.9%, respectively. In addition to this, indispensable primary resistance rate was reported in other continents; Europe (13.0%), South America (7.2%), and Africa (5.7%) in descending order.

### Primary Dual and Multiple Antibiotic Resistances {#S0003-S2002-S3005}

A higher multiple antibiotic resistance rate was reported from Turkey (n=98) CLR-MTR-LVX 18.1% and out of 110 American *H. pylori* positive patients, 1.8% were resistant for CLR-MTR-LVX and for CLR-MTR, 5.5% for CLR-LVX and MTR-LVX.[@CIT0023] In Poland among 67 participants 32.5%, 1.5%, and 4.5% individuals were non-susceptible for CLR-MTR, CLR-LVX and MTR-LVX, respectively.[@CIT0025] Above the multiple drug resistance, a higher dual resistance rate was also seen in Turkey (n=98); 45.4% and 27.2% to CLR-MTR and to CLR-LVX resistance rate were reported, respectively.[@CIT0023] In addition, dual resistance pattern of 1.8% was reported to MTR/CLR in Singapore. About10.5% (n=76) of Peruvian patients were resistant for AMX/CLR which are parts of the standard triple therapy regimen ([Table 1](#T0001){ref-type="table"}).Table 1Primary Resistance Pattern of *Helicobacter pylori* to Antibiotics Across Different Countries 2015--2017Author(s) and YearCountryNo. of Participants (n)Study PeriodPrevalence of Primary Antibiotic ResistanceAMXCLRMTRLVXZhang et al 2015[@CIT0021]China3752009--100.067(0.0478--0.0996)0.399(0.3517--0.4504)0.668(0.6202--0.7150)0.345(0.3003--0.3962)Zhang et al 2015[@CIT0021]China9502013--140.044(0.0329--0.0592)0.526(0.4945--0.5579)0.638(0.6079--0.6689)0.548(0.5166--0.5798)Caliskan et al 2015[@CIT0024]Turkey982012--1300.367(0.2786--0.4661)0.355(0.2693--0.4557)0.295(0.2146--0.3926)Ferenc et al 2017[@CIT0025]Poland672011--1300.552(0.4336--0.6652)0.567(0.4481--0.6790)0.059(0.0235--0.1437)Ang et al 2016[@CIT0026]Singapore1702012--140.041(0.0201--0.0825)0.171(0.1215--0.2343)0.482(0.4085--0.5570)0.147(0.1016--0.2081)Boehnke et al 2017[@CIT0027]Peru762011--130.329(0.2338--0.4406)0.355(0.2570--0.4674)0.618(0.5060--0.7194)0.539(0.4282--0.6469)Tamayo et al 2017[@CIT0028]Spain912014--15NA0.077(0.0378--0.1504)NANAShiota et al 2015[@CIT0029]America1102009--1300.145(0.0916--0.2233)0.173(0.1135--0.2541)0.291(0.2142--0.3817)Eng et al 2015[@CIT0030]Canada202012--1300.40(0.2188--0.6134)0.35(0.1812--0.5671)0.30(0.1455--0.5190)Sanches et al 2016[@CIT0031]Brazil4902012--15NA0.169(0.1388--0.2051)NANAMiftahussurur et al 2016[@CIT0032]Nepal42201200.214(0.1171--0.3594)0.881(0.7500--0.9481)0.429(0.2912--0.5779)Liou et al 2015[@CIT0033]Taiwan13952000--120.023(0.0169--0.0330)0.112(0.0970--0.1302)0.257(0.2351--0.2809)0.088(0.0744--0.1042)Bouihat et al 2016[@CIT0034]Morocco177201400.254(0.1958--0.3231)0.401(0.3318--0.4747)0.107(0.0698--0.1616)Zaki et al 2016[@CIT0035]Egypt462014--150.478(0.3412--0.6186)0.608(0.4646--0.7361)0.217(0.1226--0.3557)NAHarrison et al 2017[@CIT0036]Nigeria1112010--130.333(0.2525--0.4253)0.144(0.0907--0.2214)0.991(0.9507--0.9984)NA[^1]

### Overall Resistance {#S0003-S2002-S3006}

From a total of 14 studies retrieved with a total of 4218 study participants of *H. pylori* positive patients, the overall pooled primary resistance was found; 4.55% at 95% CI: 3.96--5.22% for AMX, 27.22% at 95% CI: 25.89--28.58% for CLR, 39.66% at 95% CI: 38.20--41.15% for MTR, and 22.48% at 95% CI: 21.24--23.76% for LVX. These studies were from different continents including from Europe, North America, South America, Asia and Africa. These studies had used different methods of testing antibiotic susceptibility ([Table 2](#T0002){ref-type="table"}).Table 2Overall Primary Resistance Pattern of *Helicobacter pylori* to Antibiotics in Adult Population Across Different Continents 2015--2017CountryNo. of ParticipantsOverall Prevalence of Primary Antibiotic ResistanceAMXCLRMTRLVXEurope25600.3125(0.2588--0.3717)0.2852(0.2333--0.3433)0.1289(0.0933--0.1755)North America13000.1850(0.1273--0.2600)0.2000(0.1403--0.2769)0.2923(0.2210--0.3756)South America5660.0442(0.0301--0.0644)0.1943(0.1639--0.2290)0.0830(0.0630--0.1087)0.0724(0.0538--0.0968)Asia27320.0395(0.0328--0.0478)0.3093(0.2922--0.3269)0.4890(0.4703--0.5078)0.2990(0.2822--0.3165)Africa3340.1766(0.1395--0.2212)0.2665(0.2219--0.3163)0.5719(0.5183--0.6238)0.0569(0.0367--0.0871)Overall42180.0455(0.0396--0.0522)0.2722(0.2589--0.2858)0.3966(0.3820--0.4115)0.2248(0.2124--0.2376)

Discussion {#S0004}
==========

The treatment success of *H. pylori* eradication achieved by first-line treatment with a proton pump inhibitor, CLR and AMX have decreased to 70--85% due to increasing CLR resistance.[@CIT0006] Unlike De Francesco et al[@CIT0015] consideration where improved knowledge in drug resistance strategies can result in better infection control, the safe and effective way of bacterial infection prevention and control seems difficult to touch.

The present study found higher resistance rate of CLR recorded in Europe, Asia and Africa. In addition, highest rate of non-susceptibility was seen in Asia for MTR and LVX. Concurrent to this, other worldwide systematic review reported, the overall rate of *H. pylori* antibiotic resistance was found 11.2% to AMX, 17.2% to CLR, 26.7% to MTR, and 16.2% to LVX. The prevalence rate of CLR, MTR and LVX resistance was significantly increased from Europe to Asia, Northern America and Africa.[@CIT0013] This might be due to irrational use of antibiotics. Similarly, other study also addressed the rate of *H. pylori* antibiotic resistance were 14.7% to AMX, 19.7% to CLR, 47.2% to MTR, and 18.9% to LVX. The prevalence rate of MTR and AMX resistance was higher in Africa, while CLR and LVX resistance was higher in North America and Asia, respectively.[@CIT0037] Compared to these studies, the primary resistance rate towards CLR substantially increased from 17.2%[@CIT0013] 19.7%[@CIT0037] to 27.2%. LVX resistance was also increased from 16.2%[@CIT0013] to 22.5%. Despite the over consumption of AMX and MTR the frequency of non-susceptibility rate of these antibiotics was found decreased. This was in contrary to previous studies.[@CIT0013],[@CIT0037] This might be due to the recent implementation of antimicrobial stewardship and rational antimicrobial practice awareness creation.[@CIT0038] However, even in the recent implementation of the programs the other above mentioned antibiotics resistance rate is substantially increased which necessities other studies to be undertaken.

Country specific systematic review studies reported 16.0%, 22.4%, 61.6%, and 5.3% in Iran;[@CIT0039] 9.7%, 24.8%, 33.7%, and 23.8% in Turkey;[@CIT0038] 4%, 12%, and 53% in Latin America (no for LVX);[@CIT0041] 3.1%, 28.9%, 63.8%, and 28.0%, in China[@CIT0042] to AMX, CLR, MTR and LVX, respectively. The resistance pattern for MTR and LVX was diffused and higher especially to MTR. AMX resistance in Latin America and China was comparable however Turkish and Iranian reviews reported double and almost four times higher from the present study.[@CIT0039]--[@CIT0042] This shows the antibiotic susceptibility pattern of *H. pylori* could not be predicted arbitrary in any country mandating that implementation of local drug susceptibility surveillance program and appropriate or rational prescribing and use of antibiotics is necessary.

Individual and dual antibiotic resistance significantly influences the successful eradication of the bacterial infection. The Maastricht V 2016 guideline report articulates resistance to CLR affect the efficacy of both sequential and triple treatment methods and resistance to MTR affects the treatment success by sequential therapy. Moreover, the report also had reported resistance to CLR and MTR affects the efficacy of sequential, hybrid and concomitant therapy of *H. pylori* eradication treatment protocols. According to this empirical triple therapy is discouraged. When the resistance of *H. pylori* is greater than 15% towards CLR at the specified area the treatment should be based on susceptibility pattern to other antibacterials.[@CIT0043]

Multi-resistant strains of *H. pylori* result in life-long infection that might lead to death.[@CIT0044],[@CIT0045] With the reserved treatment alternatives,[@CIT0043],[@CIT0046] a study conducted by Olleik et al on temporin-SH and its analogs resulted in good activity against resistant strains of *H, pylori* which should be taken as promising treatment alternatives for the eradication of resistant *H. pylori* infection.[@CIT0047]

Appropriate surveillance programs, improved antimicrobial regulations and increased public awareness to region-specific resistance rate of *H. pylori* isolates are possible mechanisms of prevention for *H. pylori* associated drug resistance.[@CIT0041],[@CIT0048],[@CIT0049] Therefore, drug susceptibility result of these antibiotics is necessary to select the appropriate drug for the successful eradication of the infection. This fosters rational drug prescribing practice improve patient treatment outcome and avoid unnecessary medical and nonmedical expenditure.

Conclusion {#S0005}
==========

The primary antibiotic resistance of *H. pylori* is increasing worldwide. The overall resistance rate was found to be 4.55% at 95% CI (3.96--5.22) for amoxicillin; 27.22% at 95% CI (25.89--28.58) for clarithromycin; 39.66% at 95% CI (38.20--41.15) for metronidazole; and 22.48% at 95% CI (21.24--23.76) for levofloxacin. The antibiotic susceptibility pattern of the *H. pylori* could not be predicted arbitrary in any country mandating that implementation of local drug susceptibility surveillance program and appropriate or rational prescribing and use of antibiotics as necessary.
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[^1]: **Abbreviations:** AMX, amoxicillin; CLR, clarithromycin; LVX, levofloxacin; MTR, metronidazole; NA, not analyzed.
